Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Zymeworks Inc. ( ZYME ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Shrinal Inamdar - Director of Investor Relations Leone Patterson - Executive VP and Chief Business & Financial Officer Sabeen Mekan - Senior Vice President of Clinical Development Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chairman of the Board, CEO & President Conference Call Participants Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Yaron Werber - TD Cowen, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Brian Cheng Mayank Mamtani - B. Riley Securities, Inc., Research Division Robert Burns - H.C.
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zymeworks (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know
Zymeworks (ZYME) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Shareholder/Analyst Call October 23, 2025 3:30 PM EDT Company Participants Sabeen Mekan - Senior Vice President of Clinical Development Stuart Barnscher Conference Call Participants Patricia LoRusso Mayank Mamtani - B. Riley Securities, Inc., Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Presentation Operator Thank you for standing by.
Zymeworks halts development of cancer drug after trial setback
Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Phase 3 data for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, a much larger opportunity. Partnerships with Jazz and BeiGene provide non-dilutive funding and milestone payments, but limit Zymeworks' upside to royalties and milestones.
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
